London-based biotech startup PolyModels Hub has raised £7 million in a Series A funding round, led by Molten Ventures with support from Marathon Venture Capital, to transform biopharma process development.
- PolyModels Hub, founded in 2023 by Antonio Benedetti, Harry Christodoulou, PhD, and Antonio Yankey, is a biotech software company focused on digitizing biopharma process development.
- The firm develops ModelFlow, a platform that integrates scientific data, physics-based and AI-driven models, and enterprise workflows to help process scientists and engineers design, simulate, and optimize pharmaceutical manufacturing processes.
- ModelFlow replaces traditional, experiment-heavy workflows with predictive, scalable digital processes. Early deployments have cut experimental workloads by over 90%, turning 100-experiment workflows into fewer than ten while maintaining scientific rigor. The platform supports small molecules, biologics, oligonucleotides, sterile formulations, and vaccines.
- By connecting data, models, and teams in a single environment, PolyModels Hub enables faster, more reliable decisions across the CMC and MSAT lifecycle, accelerating the delivery of medicines to patients.
"The pharmaceutical industry is undergoing a once-in-a-generation digital transformation. In just 18 months, our technology and exceptional team have delivered tangible value across multiple programs, expanding these collaborations to a global scale. We’re investing deeply in complex biologics and advancing our platform to empower scientists with the model-based solutions they deserve to transform molecules into medicines for the 21st century," said Antonio Benedetti, CEO and co-founder of PolyModels Hub.
Details of the deal
- The investment was led by Molten Ventures, a UK-based VC firm that backs tech startups with €5–20 million investments from Series A to growth equity stages, with participation from Marathon Venture Capital.
“PolyModels Hub is solving a real pain point for pharma teams, bringing together deep domain expertise and cutting-edge technology in a way that’s genuinely transformative. We’re proud to support Antonio B, Antonio Y, Harry and the team as they scale their impact across the industry. What impressed us most is the team’s blend of technical know-how and deep understanding of their customers’ challenges. They’ve built a solution that delivers value in weeks, not years, and its rapid adoption across the industry speaks volumes," claims Ben Wilkinson, CEO of Molten Ventures.
- The Series A funding will enable the firm to expand its engineering and product teams, enhance its core platform ModelFlow, and reach more pharmaceutical organizations worldwide. The company will focus on developing scalable solutions for process and regulatory workflows, making it easier for customers to adopt and benefit from its technology and accelerate the digital transformation of biopharma process development.
